Literature DB >> 23322546

A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.

Brian Godman, Lars L Gustafsson.   

Abstract

Mesh:

Year:  2013        PMID: 23322546     DOI: 10.1007/s40258-012-0008-7

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


× No keyword cloud information.
  4 in total

1.  Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations.

Authors:  Linda Björkhem-Bergman; Eva Andersén-Karlsson; Richard Laing; Eduardo Diogene; Oyvind Melien; Malena Jirlow; Rickard E Malmström; Sabine Vogler; Brian Godman; Lars L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

2.  Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.

Authors:  Rick A Vreman; Thomas F Broekhoff; Hubert Gm Leufkens; Aukje K Mantel-Teeuwisse; Wim G Goettsch
Journal:  Int J Environ Res Public Health       Date:  2020-11-10       Impact factor: 3.390

3.  Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

Authors:  Rickard E Malmström; Brian B Godman; Eduard Diogene; Christoph Baumgärtel; Marion Bennie; Iain Bishop; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Alessandra Ferrario; Alexander E Finlayson; Jurij Fürst; Kristina Garuoliene; Miguel Gomes; Iñaki Gutiérrez-Ibarluzea; Alan Haycox; Krystyna Hviding; Harald Herholz; Mikael Hoffmann; Saira Jan; Jan Jones; Roberta Joppi; Marija Kalaba; Christina Kvalheim; Ott Laius; Irene Langner; Julie Lonsdale; Sven-Äke Lööv; Kamila Malinowska; Laura McCullagh; Ken Paterson; Vanda Markovic-Pekovic; Andrew Martin; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Steven Simoens; Cankat Tulunay; Dominik Tomek; Luka Vončina; Vera Vlahovic-Palcevski; Janet Wale; Michael Wilcock; Magdalena Wladysiuk; Menno van Woerkom; Corrine Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-05-14       Impact factor: 5.810

4.  Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.

Authors:  Thomas Morel; Francis Arickx; Gustaf Befrits; Paolo Siviero; Caroline van der Meijden; Entela Xoxi; Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2013-12-24       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.